

# Renata Sano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2217467/publications.pdf>

Version: 2024-02-01

7  
papers

548  
citations

1307594

7  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

1206  
citing authors

#	ARTICLE	IF	CITATIONS
1	The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. <i>Cancer Discovery</i> , 2016, 6, 96-107.	9.4	144
2	Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. <i>Cancer Cell</i> , 2016, 29, 159-172.	16.8	104
3	Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 948-960.	7.0	86
4	Mitochondria-associated ER membranes (MAMs) and lysosomal storage diseases. <i>Cell Death and Disease</i> , 2018, 9, 328.	6.3	84
5	Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 2856-2868.	7.0	76
6	An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	44
7	Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1400-1411.	4.1	10